Adipose Derived Stem Cell TherapyMarket Regional Analysis
North America is expected to holda dominant position in the global AdiposeDerived Stem Cell Therapy Market and account the largest market shareduring the forecast period, owing to high presence of key players in theregion, which are engaged in research & development activities andimplementing in-organic growth strategies such as acquisition and collaborationto increase its market presence.
For instance, in December 2017,Mesoblast Limited made exclusive license agreement with TiGenix NV, throughwhich Mesoblast granted TiGenix an exclusive access to certain of its patentsto support global commercialization of Cx601, adipose derived mesenchymal stemcell product, for the local treatment of fistulae.
Adipose derived stem cells(ADSCs) are stem cells derived from adipocytes, and can differentiate intovariety of cell types. ADSCs have multipotency similar to bone marrowmesenchymal stem cells, thus ADSCs substitute for bone marrow as a source ofstem cells. Numerous manual and automatic stem cell separation procedures areadopted in order to separate adipose stem cells (ASCs) from adipose tissue. Flowcytometry can also be used to isolate ADSCs from other stem cells within a cellsolution.
Adipose derived stem cells aregaining appeal as a new cell source in regenerative medicine therapies as itcan be differentiated into a variety of different cell lineages. These stemcells also have anti-apoptotic, anti-inflammatory, pro-angiogenic,immunomodulatory, and anti-scarring properties, which enhances itseffectiveness.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2357
Adipose Derived Stem Cell TherapyMarket Drivers
High effectiveness of adipose derivedstem cell therapy in various medical and biotechnology research fields coupledwith growing research and development activities by various researchorganizations is expected to boost the adoption of adipose-derived stem celltherapy in the market during the forecast period. Adipose derived stem cells(ADSCs) have various applications in medical and biomedical science field suchas treatment of diabetes; regeneration of tissues partially in osteogenic,adipogenic, chondrogenic, and cardiovascular areas of medicine; boneregeneration; fat reconstruction; and myocardial and cardiovascularregeneration; among others.
For instance, in November 2018, apeer-reviewed case study conducted using a stem cell processed by CelltexTherapeutics Corporation, showed the improvement in disease findings followingsystemic administration of autologous adipose derived mesenchymal stem cells(MSCs).
Adipose Derived Stem Cell TherapyMarket Restraint
High cost associated with stemcell processing, need of skilled professional for managing, preserving, andscale-up of stem cell lines are the limiting factors, which are expected torestrain the growth of the adipose derived stem cell therapy market during theforecast period.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/adipose-derived-stem-cell-therapy-market-2357
For instance, Bioinformant— aresearch firm engaged in stem cell research— released a data on November 2018,on cost of stem cell therapy and various key factors impacting the cost of stemcell therapy including types of stem cells used within procedure, number of treatment,and the site of the clinic. The study findings reveal the cost of stem celltherapy ranges between US$ 5,000-8,000 per patient, in some cases it may riseas much as US$ 25,000 or more depending on the complexity of the procedure.
Adipose Derived Stem Cell TherapyMarket Key Players
Key players operating in theglobal adipose derived stem cell therapy market include BioRestorativeTherapies, Inc., Celltex Therapeutics Corporation, Antria, Inc., CytoriTherapeutics Inc., Intrexon Corporation, Mesoblast Ltd., iXCellsBiotechnologies, Pluristem Therapeutics, Inc., Thermo Fisher Scientific, Inc.,Tissue Genesis, Inc., Cyagen US Inc., Celprogen, Inc., and Lonza Group, amongothers.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2357
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
